• Curasight submitted a protocol amendment for its Phase I uTREAT trial in glioblastoma to regulators, pending approval.
• Update adds a new cohort without mannitol blood-brain barrier disruption, raising minimum enrollment to ensure at least six such patients.
• Enrolment is expected to take longer if the changes clear regulatory and ethics review.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Curasight A/S published the original content used to generate this news brief via Cision (Ref. ID: 202607270101BITN____UKPR__EN_20260726-BIT-1878-0) on July 27, 2026, and is solely responsible for the information contained therein.